Breast Implant Illness: Clinical Definition and Recognition

Introduction to BII

• The American College of Radiology recognizes breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) as a rare T-cell lymphoma arising in the implant capsule, distinct from breast implant illness (BII), which is a broader syndrome of nonspecific systemic symptoms 1, 2, 3.

Clinical Distinctions

• BIA-ALCL presents with late-onset seroma (>1 year post-implantation), typically 8-10 years after placement, and requires CD30 positivity for diagnosis, whereas BII does not have a single pathognomonic finding 1, 2, 5, 6.
• BIA-ALCL is associated predominantly with textured implants and can progress and cause death if untreated, according to the Journal of Clinical Oncology 1, 2, 3, 6, 7.

Implant Characteristics

• The American College of Radiology notes that BII symptoms do not correlate with implant type (saline vs. silicone), surface texture, fill material, duration of implantation, or location of original surgery, distinguishing it from BIA-ALCL 1, 2.